Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-OLIGO phase III multidisciplinary therapy with local ablative therapy plus immune-checkpoint inhibitor maintenance in synchronous oligometastatic NSCLC
jRCTs041250114Phase 3Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Overall survival. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041250114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250114.